Yusheng Han Acquires 111,110 Shares of Burning Rock Biotech (NASDAQ:BNR) Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han purchased 111,110 shares of the stock in a transaction on Tuesday, June 16th. The shares were acquired at an average cost of $9.00 per share, for a total transaction of $999,990.00. Following the transaction, the director owned 18,018,546 shares of the company’s stock, valued at approximately $162,166,914. The trade was a 0.62% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han acquired 24,900 shares of Burning Rock Biotech stock. The stock was bought at an average cost of $8.00 per share, for a total transaction of $199,200.00.
• On Wednesday, June 24th, Yusheng Han purchased 250,000 shares of Burning Rock Biotech stock. The stock was bought at an average cost of $8.00 per share, for a total transaction of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han purchased 5,990 shares of Burning Rock Biotech stock. The shares were purchased at an average cost of $7.50 per share, with a total value of $44,925.00.
• On Monday, June 22nd, Yusheng Han bought 104,650 shares of Burning Rock Biotech stock. The shares were purchased at an average cost of $7.45 per share, with a total value of $779,642.50.
• On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $9.25 per share, with a total value of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han purchased 24,760 shares of Burning Rock Biotech stock. The stock was bought at an average price of $8.74 per share, with a total value of $216,402.40.

Burning Rock Biotech Stock Performance

NASDAQ:BNR opened at $8.96 on Thursday. The stock has a fifty day moving average price of $12.79 and a 200-day moving average price of $20.08. The company has a market cap of $94.26 million, a price-to-earnings ratio of -10.93 and a beta of 1.33. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.81 and a current ratio of 3.05. Burning Rock Biotech Limited Sponsored ADR has a fifty-two week low of $3.22 and a fifty-two week high of $41.72.

Burning Rock Biotech (NASDAQ:BNR) last posted its quarterly earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.29) by $2.09. The business had revenue of $15.66 million for the quarter, compared to analyst estimates of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Wall Street Zen cut Burning Rock Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Crcm LP lifted its stake in shares of Burning Rock Biotech by 121.8% in the 4th quarter. Crcm LP now owns 491,426 shares of the company’s stock valued at $9,902,000 after acquiring an additional 269,851 shares during the last quarter. Renaissance Technologies LLC grew its position in Burning Rock Biotech by 13.8% during the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after acquiring an additional 4,290 shares during the last quarter. Prospera Financial Services Inc increased its holdings in Burning Rock Biotech by 26.0% in the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after purchasing an additional 6,430 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in Burning Rock Biotech in the 4th quarter worth about $220,000. 30.03% of the stock is currently owned by institutional investors and hedge funds.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.